—
In the rapidly evolving global consumer healthcare market, MedPlus, an AI-driven medical innovation enterprise, has successfully secured tens of millions of RMB in Series B funding. This capital injection will accelerate the development of a revolutionary precision anti-aging ecosystem and support the company’s strategic expansion in the global consumer healthcare sector. MedPlus has previously garnered support from prominent investors, including Alibaba angel investor Jiong Wu, Fosun Group, Gaorong Capital, ZhenFund, Huadan angel Investment, Real Value Capital, IN Capital, and Doctors Available Group. The company’s upcoming Series C round has already gained substantial backing, with over half of the funding target confirmed by major institutional investors. These strategic partners will help MedPlus deepen its industry footprint and drive its global expansion plans.
The company's founding team brings over a decade of mature know-how in both international business and medical service sectors, with extensive experience in cross-border consumer healthcare and medical aesthetics supply chain. Through MEDPLUS AI model, the company is to create a unique closed-loop ecosystem that integrates premier medical experts, medical aesthetics facilities, consumer interactions, specialized services, and advanced products to deliver highly personalized premium anti-aging solutions throughout the customer lifecycle.
"Our MEDPLUS AI model under development represents our dedication to breakthrough in personalized anti-aging care," said Shu Su, Chairman of MedPlus. An accomplished internet healthcare innovator, Su hold degrees from the National University of Singapore, Stanford University, and Princeton University. Having worked at Google headquarters and Goldman and also was selected for Forbes' "30 Under 30 Asia" list and recognized as one of "China's Top 10 Makers" and "2017 China Economic Top 10 Trendsetting Figures."
The MedPlus core team boasts extensive experience in Fortune 500 medical device supply chain management and has successfully commercialized numerous medical projects funded by leading institutions. With deep expertise in strategic and capital growth consulting, the team has served nearly 100 enterprises, earning accolades such as inclusion in the “China Industrial Innovation 100” and recognition among the “China High-Tech High-Growth 50.” Their global perspective and strong industry network uniquely position MedPlus for sustained innovation and worldwide growth.
Key Highlights of MedPlus's Innovative Ecosystem:
1. AI Technology: The groundbreaking MEDPLUS AI platform combines multi-dimensional data from medical experts, consumer healthcare institutions, customer interactions, and product providers. Advanced machine learning algorithms enable tailored treatment plans for each customer.
2. Medical Expert Network: Over 2,000 leading doctors and specialists contribute to a standardized and high-quality service framework, ensuring precision and consistency in anti-aging solutions.
3. Smart Supply Chain Solutions: A vast portfolio of over 4,000 SKUs, supported by 350 supply chain partners, forms an efficient cross-border network with rapid clearance times ranging from 7 to 45 days.
4. Industry Expertise: With over a decade of experience and robust partnerships, MedPlus has built a strong ecosystem for long-term collaboration and growth.
Seizing Market Opportunities
As the global anti-aging market thrives, MedPlus is at the forefront of innovation. According to China Insights Consultancy, the market reached $120 billion in 2023, with China as one of the fastest-growing segments, expected to surpass RMB 300 billion by 2028. AI-driven advancements in the sector are poised to deliver growth dividends, boosting operational efficiency and market expansion.
By establishing an AI-powered, one-stop anti-aging service system, MedPlus has demonstrated the unique value of its innovative business model. Its intelligent platform effectively matches medical resources with customer needs while optimizing supply chain efficiency. This has led to strong cash flow and a sustainable profitability model.
MedPlus is actively expanding into international markets by broadening its product offerings and deepening channel penetration. Its competitive advantages of high-threshold medical resource integration capabilities and global layout capabilities provide the company with a broad market for strategic acquisitions and industry integration. Inspired by the operational excellence of the Danaher Business System (DBS), MedPlus’ model highlights significant value creation potential. At present, with its leading position in the industry and abundant cash flow, the company has begun to look for high-quality M&A targets around the world.
Co-Founder Gavin Wu Cibin stated:
"Building an AI-driven, globally integrated anti-aging platform aligns perfectly with our team’s expertise and market insights. With over a decade of industry experience, we’ve developed a mature business model that has earned widespread recognition from investors and partners. Transitioning from 'In China, For Global' to 'In Global, For Global,' we aim to integrate premium anti-aging resources worldwide, deepen AI R&D collaboration, and accelerate product globalization. Together with our partners, we are poised to achieve greater heights in the global capital market.”
About MedPlus
MedPlus is dedicated to transforming the consumer healthcare industry with AI-driven precision anti-aging solutions. By merging cutting-edge technology with top-tier medical resources, MedPlus delivers personalized healthcare experiences while creating new value across the consumer healthcare ecosystem.
For more details about MedPlus or to explore collaboration and investment opportunities, please contact:
Contact Info:
Name: Gavin Wu
Email: Send Email
Organization: Medplus Global Healthtech
Website: http://mingyizhudao.com
Release ID: 89147343
Google
RSS